-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TNP-2092 in Prosthetic Joint infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TNP-2092 in Prosthetic Joint infections report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.TNP-2092 in Prosthetic Joint infections Drug Details:TNP-2092 (CBR-2092) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Axitinib in Choroidal Neovascularization
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Axitinib in Choroidal Neovascularization report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Axitinib in Choroidal Neovascularization Drug Details: Axitinib is under development for...
-
Track & Monitor
Innovation in medical: microneedle drug delivery
Our team of industry experts has meticulously researched and analyzed the latest trends, innovations and emerging technologies in the medical industry’s microneedle drug delivery segment. By leveraging our report, you will gain invaluable insights that can revolutionise your business strategies and give you a competitive edge. Note: This is an “on-demand” report and will be delivered within 2 to 4 business days (excluding weekends and holidays) of the purchase. Certain sections in the report may be removed or altered based...
-
Product Insights
Uveitis Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Uveitis Clinical Trials Market Report Overview The uveitis clinical trial market research report provides an overview of the uveitis clinical trials scenario. The report provides top-line data relating to the clinical trials on uveitis. It also includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. Moreover, it offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status, and sponsor type. Key Regions North America,...
-
Company Profile
Clearside BioMedical Inc – Company Profile
Clearside BioMedical Inc (Clearside) is a clinical biopharmaceutical company that develops treatments for vision impairment associated with uveitic macular edema. The company’s pipeline products comprise CLS-AX, XIPERE and SCS microinjectors. Clearside’s proprietary suprachoroidal treatment approach offers unprecedented access to the back of the eye where sight-threatening disease often occurs. The company also offers services such as business development, license agreements and contract manufacturing services. Clearside has partnered with various pharmaceutical companies for the commercialization and development of its products across...
Add to Basket -
Product Insights
Macular Edema Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Macular Edema is swelling or fluid retention in a specialized part of the retina called the macula. Symptoms of macular edema include blurred or wavy central vision and/or colors appear changed. There are many causes of macular edema. It is frequently associated with diabetes, where damaged blood vessels in the retina begin to leak fluids, including small amounts of blood, into the retina. Other causes include retinal vein occlusion, side effects of certain medications and certain genetic disorders, such as...
-
Product Insights
Usher Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Usher syndrome is an inherited condition characterized by hearing impairment and progressive vision loss. The major symptoms of Usher syndrome are hearing loss and an eye disorder called retinitis pigmentosa. Risk factors include retinal degeneration and prolonged and unprotected exposure to sunlight may accelerate vision loss. Treatment includes cochlear implants, hearing aids, and Vitamin A supplementation. The Usher syndrome pipeline market research report provides comprehensive information on the therapeutics under development for Usher syndrome, complete with analysis by stage of...
-
Product Insights
Net Present Value Model: Xipere
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Xipere Drug Details Triamcinolone acetonide (Xipere)...
-
Product Insights
Net Present Value Model: Axitinib
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Axitinib Drug Details Axitinib (OTX-TKI) is...
-
Track & Monitor
Internet of Things in Pharmaceuticals: Microneedles for transdermal drug delivery
Our team of industry experts has meticulously researched and analyzed the latest trends, innovations and emerging technologies in the Pharmaceuticals industry’s Microneedles for transdermal drug delivery segment. By leveraging our report, you will gain invaluable insights that can revolutionise your business strategies and give you a competitive edge. Note: This is an “on-demand” report and will be delivered within 2 to 4 business days (excluding weekends and holidays) of the purchase. Certain sections in the report may be removed or...